Loading...

Summit Therapeutics Inc.

SMMT•NASDAQ
Healthcare
Biotechnology
$22.08
$-0.19(-0.85%)
U.S. Market opens in 49h 27m

Summit Therapeutics Inc. (SMMT) Stock Overview

Explore Summit Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap17.1B
P/E Ratio-15.08
EPS (TTM)$-1.44
ROE-2.97%
Fundamental Analysis

AI Price Forecasts

1 Month$15.73
3 Months$11.93
1 Year Target$22.16

SMMT Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Summit Therapeutics Inc. (SMMT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 56.77, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $22.16.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -15.08 and a market capitalization of 17.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.85%
5-Day Change
-10.06%
1-Month Change
42.08%
3-Month Change
33.90%
6-Month Change
14.52%
Year-to-Date (YTD) Change
26.24%
1-Year Change
-39.84%
3-Year Change
1362.25%
5-Year Change
266.17%
All-Time (Max) Change
116.68%

Contact Information

https://www.summittxinc.com
617 514 7149
One Broadway, Cambridge, MA, 02142

Company Facts

159 Employees
IPO DateMar 5, 2015
CountryUS
Actively Trading

Frequently Asked Questions